Tracking PrEP Rollout & Learning Lessons
View this email in your browser ([link removed])
[link removed] May 29, 2024
** Tracking PrEP Rollout & Learning Lessons
------------------------------------------------------------
Dear Advocate,
Accelerating the rollout of the full range of proven HIV prevention options depends on learning from what’s been done in the past and investing in coordination and innovation to put improved solutions in place. The Biomedical Prevention Implementation Collaborative ([link removed]) (BioPIC) ([link removed]) is doing just that. Over the last two years, BioPIC – a project led by AVAC with support from the Gates Foundation – has been gathering and sharing evidence on these critical lessons to ensure the next generation of HIV prevention products reaches everyone who needs and wants them with much greater speed and equity.
What We’re Learning—Highlights from 2024 Convenings
An ongoing series of think tanks, convened by BioPIC and WHO since 2021, are generating key insights for people-centered product delivery. Below, read the latest reports from these think tanks ([link removed]) that are informing decision-making on priorities for accelerating access to PrEP. Go to the BioPIC’s page on PrEPWatch ([link removed]) to find reports on all think tanks since 2021.
** Early Insights from EBONI and PILLAR, February 2024
------------------------------------------------------------
Early insights from ViiV Healthcare, the manufacturer of CAB for PrEP, from two CAB for PrEP implementation studies, EBONI ([link removed]) and PILLAR. ([link removed]) Conducted by ViiV in the US, these are among the first studies gathering data in real-world settings. Learn more ([link removed])
** Taking Stock of PrEP Evidence, March 2024
------------------------------------------------------------
An analysis of current data and priority evidence gaps. This inquiry was not focused on any one PrEP product, and its findings are informing the focus of future think tanks. Learn more ([link removed])
** Linking Modellers with the Latest Implementation Science Evidence, March 2024
------------------------------------------------------------
A consideration of the latest modelling data and insights on injectable cabotegravir (CAB) for PrEP. Read about the biggest takeaways from CAB for PrEP modelling here ([link removed]) , and learn more about the big questions that require further inquiry here ([link removed]) .
** Discussing Early Results from the SEARCH Dynamic Choice Study, April 2024
------------------------------------------------------------
Professor Moses Kamya of Makerere University shares early insights from the SEARCH Dynamic Choice Study in Kenya and Uganda, which gave participants a choice between oral PrEP, PEP, and CAB for PrEP, and analyzes the role of choice in PrEP coverage. Watch here ([link removed])
** PrEP and the Role of HIV Self-Testing, May 23
------------------------------------------------------------
Highlights from the WHO guidance on use of self-testing (HIVST) as an innovative way to increase PrEP access and coverage and further simplify PrEP delivery. Panelists also share experiences with procurement, costing, rollout and scale-up. Watch Here ([link removed])
[link removed]
As other new biomedical HIV prevention product ([link removed]) s ([link removed]) roll out, BioPIC will continue to hold strategic convenings, identify and address evidence gaps, and work to accelerate equitable product introduction. To learn more efforts to coordinate the introduction of CAB for PrEP, check out the JIAS article Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC) ([link removed]) . To learn what’s needed to better coordinate rollout for not-yet-approved products in Phase III clinical trials, check out BioPIC’s Adaptable Product Introduction Framework ([link removed]) .
We hope you will book mark these resources, and stay up to date on findings from future think tanks and webinars in 2024 on the BioPIC page ([link removed]) of PrEPWatch. ([link removed])
Best,
AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed]) [link removed]
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423
[email protected] (mailto:
[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
